In a significant advancement for the field of oncology, a collaborative study led by investigators at the Johns Hopkins Kimmel…
Read More
Rethinking evidence generation for ultra-rare diseases
Developing treatments for ultra-rare diseases presents fundamental challenges for traditional evidence generation, necessitating a paradigm shift in how scientific rigor…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
Johns Hopkins Researchers Uncover Liquid Condensate Mechanism Driving Rare Translocation Kidney Cancer and Propose New Therapeutic Avenues
In a significant advancement for the field of molecular oncology, a multidisciplinary team of investigators at the Johns Hopkins Kimmel…
Read More
Rethinking evidence generation for ultra-rare diseases
Developing treatments for the approximately 7,000 known rare diseases, particularly the subset classified as ultra-rare, presents profound and often insurmountable…
Read More
Breakthrough Research Unveils How Gene Fusion Condensates Drive Rare Kidney Cancer Progression and Potential Treatment Pathways
Investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health have identified a…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Johns Hopkins Researchers Uncover How Gene Fusion Droplets Drive Rare Kidney Cancer Progression
In a significant advancement for the field of oncology and molecular biology, investigators at the Johns Hopkins Kimmel Cancer Center…
Read More
Rethinking evidence generation for ultra-rare diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read MoreYOU MAY HAVE MISSED
